CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
CymaBay Therapeutics (NASDAQ: CBAY) will host a conference call on November 5, 2020, at 4:30 PM ET to discuss Q3 financial results and provide a business update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CymaBay Therapeutics (NASDAQ: CBAY) will host a conference call on November 5, 2020, at 4:30 PM ET to discuss Q3 financial results and provide a business update. The company is focused on developing therapies for liver diseases and has a key product, seladelpar, which is under investigation for primary biliary cholangitis (PBC). Seladelpar has received orphan drug designation from the FDA and EMA, along with Breakthrough Therapy Designation from the FDA. For more information, visit their website.
Positive
- Seladelpar received orphan drug designation from FDA and EMA.
- Seladelpar obtained Breakthrough Therapy Designation from FDA.
Negative
- None.
Details
News Market Reaction – CBAY
The recorded move for CBAY in the trading session of this news was -2.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter and nine months ended September 30, 2020 and to provide a business update.
Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13709641. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.
About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). For PBC, seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA.
For additional information about CymaBay visit www.cymabay.com.
Public Relations Contact:
Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com
Investor Relations Contact:
Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.